Dr. Rule on Potential for CAR T-Cell Therapy in MCL

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma (MCL).

Data on using CAR T-cell therapy to treat patients with MCL will be presented at the 2019 ASH Annual Meeting. Rule is hoping CAR T-cell therapy will be a contributing treatment and believes it will work best post-BTK inhibitor.

CAR T-cell therapy may even have the potential to replace allogeneic stem cell transplant, according to Rule. This would be a positive advance because many physicians do not like the toxicity associated with allogeneic stem cell transplant, particularly graft-versus-host disease. However, long-term data are necessary before CAR T-cell therapy is used in place of allogeneic stem cell transplant, concludes Rule.

Related Videos
View All
Related Content